Sukhatme Mayukh
SEC CIK 1750050 · EDGAR
BoughtSold
Companies
| Ticker | Company | Title | Holding | Bought | Sold | Trades | First | Last |
|---|---|---|---|---|---|---|---|---|
| ROIV | Roivant Sciences Ltd. | See Remarks | 18.78M | — | $124.75M | 31 | 2023-05-27 | 2026-08-19 |
Most active insiders at ROIV, 12 months
| # | Insider | Title | Bought | Sold |
|---|---|---|---|---|
| 1 | MANCHESTER KEITH S | Dir | — | $154.47M |
| 2 | Gold Daniel Allen | Dir | — | $147.38M |
| 3 | QVT Financial LP | Dir by Deputization | — | $147.38M |
| 4 | Sukhatme Mayukh | Pres, CIO, Dir | — | $109.13M |
| 5 | Ramaswamy Vivek | 10% | — | $105.88M |
| 6 | Venker Eric | Pres, Immunovant CEO | — | $89.77M |
| 7 | Torti Frank | Pres, Vant COB | — | $82.04M |
| 8 | Gline Matthew | CEO, Dir | — | $46.17M |
| 9 | Pulik Richard | CFO | — | $9.12M |
| 10 | Fitzgerald Meghan | Dir | — | $3.27M |
Transactions 31
| X | Filed | Traded | Ticker | Company | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| DM | 2026-08-21 21:00 | 2026-08-19+ | ROIV | Roivant Sciences Ltd. | Sukhatme Mayukh | Pres, CIO, Dir | M - OptEx | $3.85 | +335.2K | 18.78M | +2% | +$1.29M |
| DM | 2026-08-21 21:00 | 2026-08-19+ | ROIV | Roivant Sciences Ltd. | Sukhatme Mayukh | Pres, CIO, Dir | S - Sale+OE | $36.88 | -335.2K | 18.63M | -2% | -$12.36M |
| DM | 2026-08-18 21:00 | 2026-08-14+ | ROIV | Roivant Sciences Ltd. | Sukhatme Mayukh | Pres, CIO, Dir | M - OptEx | $3.85 | +664.8K | 18.66M | +4% | +$2.56M |
| DM | 2026-08-18 21:00 | 2026-08-14+ | ROIV | Roivant Sciences Ltd. | Sukhatme Mayukh | Pres, CIO, Dir | S - Sale+OE | $36.34 | -664.8K | 18.63M | -3% | -$24.16M |
| 2026-07-02 19:00 | 2026-06-30 | ROIV | Roivant Sciences Ltd. | Sukhatme Mayukh | Pres, CIO, Dir | F - Tax | $35.39 | -46.9K | 18.63M | -0.3% | -$1.66M | |
| DM | 2026-06-29 18:23 | 2026-06-25+ | ROIV | Roivant Sciences Ltd. | Sukhatme Mayukh | Pres, CIO, Dir | M - OptEx | $3.85 | +1.00M | 19.18M | +6% | +$3.85M |
| DM | 2026-06-29 18:23 | 2026-06-25+ | ROIV | Roivant Sciences Ltd. | Sukhatme Mayukh | Pres, CIO, Dir | S - Sale+OE | $34.10 | -1.00M | 18.68M | -5% | -$34.10M |
| D | 2026-04-01 19:19 | 2026-03-30 | ROIV | Roivant Sciences Ltd. | Sukhatme Mayukh | Pres, CIO, Dir | M - OptEx | — | +58.4K | 18.89M | +0.3% | — |
| DM | 2026-04-01 19:19 | 2026-03-30+ | ROIV | Roivant Sciences Ltd. | Sukhatme Mayukh | Pres, CIO, Dir | F - Tax | $27.52 | -217.3K | 18.68M | -1% | -$5.98M |
| D | 2026-02-11 | 2026-02-09 | ROIV | Roivant Sciences Ltd. | Sukhatme Mayukh | Pres, CIO, Dir | S - Sale+OE | $26.47 | -339.4K | 19.15M | -2% | -$8.99M |
| D | 2026-02-11 | 2026-02-09 | ROIV | Roivant Sciences Ltd. | Sukhatme Mayukh | Pres, CIO, Dir | M - OptEx | $12.68 | +651.6K | 19.49M | +3% | +$8.26M |
| D | 2026-02-11 | 2026-02-09 | ROIV | Roivant Sciences Ltd. | Sukhatme Mayukh | Pres, CIO, Dir | J - Other | $26.47 | -312.1K | 18.84M | -2% | -$8.26M |
| DM | 2025-12-31 | 2025-12-29+ | ROIV | Roivant Sciences Ltd. | Sukhatme Mayukh | Pres, CIO, Dir | S - Sale+OE | $21.72 | -1.33M | 20.27M | -6% | -$28.90M |
| DM | 2025-12-31 | 2025-12-29+ | ROIV | Roivant Sciences Ltd. | Sukhatme Mayukh | Pres, CIO, Dir | J - Other | $21.72 | -1.87M | 18.84M | -9% | -$40.55M |
| DM | 2025-12-31 | 2025-12-29+ | ROIV | Roivant Sciences Ltd. | Sukhatme Mayukh | Pres, CIO, Dir | M - OptEx | $12.68 | +3.20M | 19.58M | +20% | +$40.55M |
| D | 2025-12-19 | 2025-12-17 | ROIV | Roivant Sciences Ltd. | Sukhatme Mayukh | Pres, CIO, Dir | J - Other | $23.09 | -32.7K | 18.84M | -0.2% | -$754.6K |
| D | 2025-12-19 | 2025-12-17 | ROIV | Roivant Sciences Ltd. | Sukhatme Mayukh | Pres, CIO, Dir | S - Sale+OE | $23.09 | -26.8K | 18.87M | -0.1% | -$619.5K |
| D | 2025-12-19 | 2025-12-17 | ROIV | Roivant Sciences Ltd. | Sukhatme Mayukh | Pres, CIO, Dir | M - OptEx | $12.68 | +59.5K | 18.90M | +0.3% | +$754.6K |
| DM | 2024-12-26 | 2024-12-23+ | ROIV | Roivant Sciences Ltd. | Sukhatme Mayukh | Pres, CIO, Dir | S - Sale+OE | $12.01 | -886.2K | 18.84M | -4% | -$10.64M |
| DM | 2024-12-26 | 2024-12-23+ | ROIV | Roivant Sciences Ltd. | Sukhatme Mayukh | Pres, CIO, Dir | M - OptEx | $3.85 | +886.2K | 19.02M | +5% | +$3.41M |
| D | 2024-12-20 | 2024-12-18 | ROIV | Roivant Sciences Ltd. | Sukhatme Mayukh | Pres, CIO, Dir | S - Sale+OE | $12.05 | -412.6K | 18.84M | -2% | -$4.97M |
| D | 2024-12-20 | 2024-12-18 | ROIV | Roivant Sciences Ltd. | Sukhatme Mayukh | Pres, CIO, Dir | M - OptEx | $3.85 | +412.6K | 19.25M | +2% | +$1.59M |
| 2024-12-05 | 2024-12-03 | ROIV | Roivant Sciences Ltd. | Sukhatme Mayukh | Pres, CIO, Dir | J - Other | $12.21 | -3.65M | 18.84M | -16% | -$44.59M | |
| M | 2024-07-30 | 2024-07-26 | ROIV | Roivant Sciences Ltd. | Sukhatme Mayukh | Pres, CIO, Dir | A - Grant | $0.00 | +18.84M | 5.49M | New | $0 |
| DT | 2024-04-02 | 2024-03-30 | ROIV | Roivant Sciences Ltd. | Sukhatme Mayukh | Pres, CIO, Dir | F - Tax | $10.54 | -366.2K | 3.65M | -9% | -$3.86M |
| DT | 2024-04-02 | 2024-03-30 | ROIV | Roivant Sciences Ltd. | Sukhatme Mayukh | Pres, CIO, Dir | M - OptEx | — | +729.1K | 4.02M | +22% | — |
| D | 2023-12-29 | 2023-12-27 | ROIV | Roivant Sciences Ltd. | Sukhatme Mayukh | Pres, CIO | M - OptEx | — | +71.4K | 3.29M | +2% | — |
| D | 2023-09-29 | 2023-09-27 | ROIV | Roivant Sciences Ltd. | Sukhatme Mayukh | Pres, CIO | M - OptEx | — | +27.8K | 3.22M | +0.9% | — |
| D | 2023-08-29 | 2023-08-27 | ROIV | Roivant Sciences Ltd. | Sukhatme Mayukh | Pres, CIO | M - OptEx | — | +22.6K | 3.19M | +0.7% | — |
| D | 2023-07-31 | 2023-07-27 | ROIV | Roivant Sciences Ltd. | Sukhatme Mayukh | Pres, CIO | M - OptEx | — | +43.2K | 3.17M | +1% | — |
| D | 2023-05-31 | 2023-05-27 | ROIV | Roivant Sciences Ltd. | Sukhatme Mayukh | See Remarks | M - OptEx | — | +99.5K | 3.12M | +3% | — |
Purchase Sale Sale after option exercise All abbreviations